AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$140M+16.3% YoY

Gross Profit

$74M52.7% margin

Operating Income

$33M23.9% margin

Net Income

$26M18.6% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

+3.7%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$31M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$774M

Total Liabilities

$225M

Stockholders' Equity

$549M

Cash & Equivalents

$177M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$140M	$120M	+16.3%
Gross Profit	$74M	$56M	+32.3%
Operating Income	$33M	$22M	+54.7%
Net Income	$26M	$24M	+7.3%

Revenue Segments

Research and development services

$100,000100%

Geographic Segments

UNITED STATES

$138M99%

FRANCE

$2M1%

CHINA

$127,0000%

AMPH Q1 2023 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena